Market Overview

UPDATE: Stifel Nicolaus Raises PT to $83 on Mednax Post Investor Day

Share:
Related MD
Analyst: Buy CRH Medical After An 'Overdone' Selloff
4 Reasons to Stay Away from Mednax Now

Stifel Nicolaus reiterated its Buy rating on Mednax (NYSE: MD) and raised its price target from $74 to $83.

Stifel Nicolaus noted, "MEDNAX demonstrated strong top-line and margin growth prospects for its American Anesthesiology division at its investor day. We are raising our target price to reflect this growth as well as pending increases to Medicaid payments to neonatologists. … We came away impressed by both the division's prospects for consolidating the anesthesiology specialty and the potential for improving affiliated practices' financial performance through the rollout of its proprietary clinical software."

Mednax closed at $75.63 on Wednesday.

Latest Ratings for MD

DateFirmActionFromTo
Jun 2017Stephens & Co.UpgradesEqual-WeightOverweight
Mar 2017BairdDowngradesOutperformNeutral
Mar 2017JP MorganDowngradesOverweightNeutral

View More Analyst Ratings for MD
View the Latest Analyst Ratings

Posted-In: Stifel NicolausAnalyst Color Price Target Intraday Update Analyst Ratings

 

Related Articles (MD)

View Comments and Join the Discussion!